. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: Xenotransplantation. 2013 Nov 5;21(1):72–83. doi: 10.1111/xen.12073

Table 1.

Genetically-modified pAEC tested in the human platelet aggregation assay

Genetic modification	Effect	Promoter
GTKO	Deletion of Gal antigen
CD46	Transgenic expression of a human complement- regulatory protein	Endogenous
CD55	Transgenic expression of a human complement- regulatory protein	CAG promoter
TFPI	Transgenic expression of human TFPI antagonizes the function of human tissue factor (inhibits FXa, thrombin, FVIIa-TF complex)	TIE2
TBM	Transgenic expression of human TBM activates protein C	Endogenous or ICAM-2 promoter
EPCR	Transgenic expression of human EPCR enhances the activation of protein C	CAG promoter

EPCR= endothelial protein C receptor

GTKO= a1,3-galactosytransferase gene-knockout

TBM= thrombomodulin

TFPI= tissue factor pathway inhibitor